Flt3/MerTK

Class

small molecule

Notes

original target text: Flt3/MerTK Inhibitor

This mechanism describes a small-molecule inhibitor that blocks two related enzymes, FLT3 and MerTK, both members of the receptor tyrosine kinase family. FLT3 is expressed on early blood-forming cells and, when mutated, becomes continuously active, driving uncontrolled proliferation of leukemic blasts—a hallmark of a substantial subset of acute myeloid leukemia. MerTK belongs to a related family of receptors involved in clearing dying cells and dampening immune responses; in cancer, its abnormal activity can help malignant cells survive treatment and evade immune surveillance. Combining inhibition of both targets in a single molecule reflects an important biological rationale: cells treated with a FLT3-only inhibitor often develop resistance in part by upregulating MerTK signaling, and MerTK also independently suppresses the immune system's ability to recognize residual disease. By addressing the primary oncogenic driver and a parallel resistance/immune-evasion pathway simultaneously, this dual-targeting approach aims to produce a more durable antileukemic effect than blocking FLT3 alone. This general strategy—pairing a driver-mutation inhibitor with a resistance-pathway inhibitor—is broadly relevant in oncology wherever tumors adapt to single-target therapy through compensatory signaling.